Symbol="OCX"
AssetType="Common Stock"
Name="OncoCyte Corp"
Description="OncoCyte Corporation, a molecular diagnostics company, researches, develops, and markets proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company is headquartered in Irvine, California."
CIK="1642380"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES"
Address="1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="28266800"
EBITDA="-22307000"
PERatio="None"
PEGRatio="0"
BookValue="5.78"
DividendPerShare="0"
DividendYield="0"
EPS="-1.8"
RevenuePerShareTTM="0.17"
ProfitMargin="0"
OperatingMarginTTM="-23.52"
ReturnOnAssetsTTM="-0.125"
ReturnOnEquityTTM="-0.238"
RevenueTTM="1101000"
GrossProfitTTM="188000"
DilutedEPSTTM="-1.8"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.776"
AnalystTargetPrice="5.19"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="6.13"
PriceToBookRatio="0.648"
EVToRevenue="2.608"
EVToEBITDA="-0.362"
Beta="1.571"
num_52WeekHigh="22"
num_52WeekLow="3.3"
num_50DayMovingAverage="4.165"
num_200DayMovingAverage="6.6"
SharesOutstanding="8241000"
DividendDate="None"
ExDividendDate="None"
symbol="OCX"
open="3.34"
high="3.48"
low="3.34"
price="3.37"
volume="4350.00"
latest_trading_day="2023-08-17"
previous_close="3.34"
change="0.03"
change_percent="0.8982%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="98"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="2"
Volume_recent_avg="272283"
Change_recent_avg="-0.01"
Delta_recent_avg="0.06"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-0.45"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="2"
Aroon_momentum_negative="98"
image_negative_thumbnail_id_1="1149"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0182.jpeg"
image_negative_thumbnail_id_2="164"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0012.jpeg"
image_neutral_thumbnail_id_1="560"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0039.jpeg"
image_neutral_thumbnail_id_2="585"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0014.jpeg"
image_positive_thumbnail_id_1="680"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0028.jpeg"
image_positive_thumbnail_id_2="984"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0146.jpeg"
image_professor_thumbnail_id_1="1196"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
image_professor_thumbnail_id_2="1174"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
